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Prescribable mHealth apps identiﬁed from an overview of
systematic reviews
Oyungerel Byambasuren 1, Sharon Sanders1, Elaine Beller1 and Paul Glasziou1
Mobile health apps aimed towards patients are an emerging ﬁeld of mHealth. Their potential for improving self-management of
chronic conditions is signiﬁcant. Here, we propose a concept of “prescribable” mHealth apps, deﬁned as apps that are currently
available, proven effective, and preferably stand-alone, i.e., that do not require dedicated central servers and continuous monitoring
by medical professionals. Our objectives were to conduct an overview of systematic reviews to identify such apps, assess the
evidence of their effectiveness, and to determine the gaps and limitations in mHealth app research. We searched four databases
from 2008 onwards and the Journal of Medical Internet Research for systematic reviews of randomized controlled trials (RCTs) of
stand-alone health apps. We identiﬁed 6 systematic reviews including 23 RCTs evaluating 22 available apps that mostly addressed
diabetes, mental health and obesity. Most trials were pilots with small sample size and of short duration. Risk of bias of the included
reviews and trials was high. Eleven of the 23 trials showed a meaningful effect on health or surrogate outcomes attributable to
apps. In conclusion, we identiﬁed only a small number of currently available stand-alone apps that have been evaluated in RCTs.
The overall low quality of the evidence of effectiveness greatly limits the prescribability of health apps. mHealth apps need to be
evaluated by more robust RCTs that report between-group differences before becoming prescribable. Systematic reviews should
incorporate sensitivity analysis of trials with high risk of bias to better summarize the evidence, and should adhere to the relevant
reporting guideline.
npj Digital Medicine  (2018) 1:12 ; doi:10.1038/s41746-018-0021-9
INTRODUCTION
The number of smartphones worldwide is predicted to reach 5.8
billion by 20201 and there are 6 million multimedia applications
(apps) available for download in the app stores.2 According to the
latest report from IQVIA Institute for Human Data Sciences
(formerly IMS Institute for Healthcare Informatics) 318,000 of
these are mHealth apps.3 As one of the prominent digital
behaviour change interventions of our time, mHealth apps
promise to improve health outcomes in a myriad of ways
including helping patients actively measure, monitor, and manage
their health conditions.4
Here, we propose a concept of “prescribable” mHealth apps,
deﬁned as health apps that are currently available, proven
effective, and preferably stand-alone. When proven effective and
available, stand-alone mHealth apps that do not require dedicated
central servers and additional human resources, can join other
simple low-cost non-pharmaceutical interventions that can be
‘prescribed’ by general practitioners (GPs).
However, although there are a number of systematic and other
reviews of mHealth apps aimed at particular health conditions
that examined different aspects of the apps such as the contents,
quality and usability,5–8 no overview of systematic reviews has
been done yet to summarize the effectiveness of stand-alone
mHealth apps speciﬁcally, and across different health conditions
that present in general practice. Overviews of reviews are an
efﬁcient way to gather the best available evidence in a single
source to examine the evidence of effectiveness of interventions.9
Hence, our objectives were to: (1) conduct an overview of
systematic reviews of randomized controlled trials (RCTs) to
identify and evaluate the effectiveness of prescribable mHealth
apps; and (2) determine the gaps and limitations in mHealth app
research.
RESULTS
Search results
The PRISMA ﬂowchart of the study selection process is presented
as Fig. 1. Our electronic searches and the other sources search
identiﬁed 981 publications. After deduplication, we screened 799
titles and abstracts, and assessed 145 full text articles for eligibility.
One hundred and sixteen full text articles were excluded: 22 did
not qualify as systematic reviews, 40 studies used non-app
intervention, 4 studies were duplicates, 6 were abstracts only, 4
articles evaluated only the contents of the apps, and 40 studies
did not meet one or more of the inclusion criteria (Supplementary
Information 1). Of the 29 articles eligible for inclusion, 3 reviews
were excluded due to apps still being unavailable and 20 reviews
were excluded because they covered the same app trials as 6
more recent systematic reviews that were included in our
overview (Supplementary Information 2).
To achieve our study objectives, we used available systematic
reviews of RCTs as a source of stand-alone mHealth apps that have
been evaluated. We then determined the availability of those apps
to ascertain the prescribability by searching the app stores and by
contacting the authors of the RCTs. Figure 2 illustrates the scope
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of our study. Due to lack of established data on each category, the
circle sizes and overlaps are illustrative.
We contacted 144 authors to determine the type and
availability of their study apps. A little over half of the authors
replied and we were able to include three app RCTs in our analysis
as a result. We also found out that 25 app projects were
discontinued.
Description of included studies
Six published systematic reviews met the inclusion criteria for this
overview.10–15 Characteristics and the limitations of the included
systematic reviews are presented in Table 1. The systematic
reviews were published between 2015–2017, and included a total
of 93 RCTs and 18 studies of other designs. However, only 23 of
the RCTs evaluated currently available stand-alone health apps.
Characteristics of these RCTs are shown in Table 2 along with
information about their availability and prescribability.
One of the systematic reviews addressed diabetes,10 two
addressed mental health,11,15 another two addressed physical
activity and weight loss related issues,12,14 and one addressed all
of these areas by addressing the behavior change aspect of
apps.13 Four of the reviews also included meta-analyses.10–12,15 We
described the systematic reviews and the RCTs in further detail
under thematic subheadings.
Fig. 1 PRISMA ﬂow diagram of selection of systematic reviews. *Table of excluded articles due to Inclusion and Exclusion criteria mismatch is
provided as Supplementary Information 1. ^Table of excluded articles due to repeated coverage is provided as Supplementary Information 2
Fig. 2 Scope of the overview
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Effects of interventions
Diabetes. The Bonoto 2017 systematic review assessed app
interventions for diabetes mellitus type 1 and 210. It included 13
RCTs, of which 5 were relevant to this overview.16–20 All of the
RCTs included apps that aimed to improve glycemic control and
quality of life as measured by multiple biochemical markers. The
meta-analysis showed a mean difference of −0.4% (95% CI −0.6,
−0.3) in glycated haemoglobin levels favoring the intervention.
Four trials tested apps for type 1 diabetes patients, of which two
demonstrated a signiﬁcant between group reduction in HbA1c
levels.17,20 One trial that tested an app for type 2 diabetes patients
did not show any between group differences in HbA1c levels at
one year.19 All the diabetes apps include functions to log blood
glucose levels, insulin dose, diet and physical activity, and to set
push notiﬁcations and reminders. Two of the apps also offer
versions for doctors to enrol and monitor multiple patients.16,18 At
this stage, only two of these diabetes apps are available free of
charge worldwide,18,20 and the other three apps are available
either in Germany, France, or Norway (Table 2).
Mental health. The Firth 2017 systematic review assessed
interventions aimed at reducing anxiety.11 It included nine RCTs,
of which two were relevant to this overview. Their meta-analysis of
the effects of smartphone interventions on symptoms of anxiety
found small-to-moderate positive effect favoring the intervention
(Hedges’ g= 0.3, 95% CI 0.2, 0.5).
Two of the RCTs from this review used stand-alone apps that
were available. A breathing retraining game app called Flowy did
not show any signiﬁcant reduction in anxiety, panic, and
hyperventilation.21 The basic version of SuperBetter app was
tested against its “fortiﬁed” version, which contains more
cognitive behavioral therapy (CBT) and positive psychotherapy
content, and a waitlist control group.22 Depression scores were
equally reduced in both app groups compared to the control
group, but the attrition rate was high (80%) in both app groups
over 4 weeks.
The Payne 2015 systematic review assessed app interventions
for their behaviour change potential.13 It included 14 RCTs and 9
feasibility and pilot studies, of which 7 RCTs were eligible for our
overview. Only one of the RCTs tested an app for depression
against a previously validated web-based CBT program.23 Both
groups had equally signiﬁcant improvements. This app is now
called Managing Depression as a part of 4 app series called This
Way Up and available for AUD 59.99.
Two other trials included in Payne 2015 systematic review
explored use of mobile apps to curb alcohol use among university
students24 and patients leaving residential treatment for alcohol
use disorder.25 The results showed that alcohol use increased
among university students who used the intervention app
Promillekoll, which calculated blood alcohol concentration up to
the legal limit.24 Whereas, the A-CHESS app that was designed to
provide on-going support for people leaving alcohol rehabilitation
was shown to reduce the risky drinking days in the previous
30 days (OR 1.94, 95% CI 1.14–3.31, p= 0.02).25 These apps are
available in Sweden and the USA respectively.
The Simblett 2017 systematic review assessed e-therapies
aimed at treating posttraumatic stress disorder (PTSD).15 It
included 39 RCTs. The meta-analysis showed standardized mean
difference of −0.4 (95% CI −0.5, −0.3) favoring the intervention in
reducing the severity of PTSD symptoms, however the hetero-
geneity was high (I2= 81), which was not explained by the
subgroup and sensitivity analysis. Only one of the RCTs tested an
app called PTSD Coach against waitlist control for 1 month;
however, there were no signiﬁcant between group differences in
the PTSD Checklist–Civilian questionnaire result.26
Weight loss and physical activity. Two systematic reviews
evaluated apps for weight loss and physical activity. The Flores-T
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Mateo 2015 systematic review assessed studies aimed at
increasing weight loss and physical activity for overweight and
obese people of all ages.12 It included nine RCTs and two case
control studies of which ﬁve RCTs were relevant to this overview.
A meta-analysis of nine studies showed app interventions reduced
weight by −1.0 kg (95% CI −1.8, −0.3) more than the control
group. Net change in body mass index (BMI) showed mean
difference of −0.4 kg/m2 (95% CI −0.7, −0.1) favoring the
intervention. Net change in physical activity resulted in standard
mean difference of 0.4 95% CI −0.1, 0.9), however, the
heterogeneity was high (I2= 93%) and the authors did not
explain why several RCTs that reported physical activity outcomes
were excluded from this meta-analysis.
Four of the RCTs from this review used calorie counting apps as
interventions.27–30 However, only one of them (MyMealMate app)
showed a statistically signiﬁcant between-group difference in
weight loss.28 The MyMealMate app includes calorie information of
23,000 UK-speciﬁc brands of food items in the database, and goal-
setting, physical activity monitoring and automated text-messages
functions. When compared against a self-monitoring slimming
website, the app group lost notable amount of weight and BMI,
but not compared to the control group that used a calorie
counting paper diary. MyFitnessPal app is one of the consistently
highest rated free apps for calorie monitoring and it contains
database of 3 million food items. However, when tested on its own
for 6 months, the intervention made almost no difference to the
weight of the participants.29 This study also provided an insight on
the usage of the apps during the trial, which showed that the
logins to the app dropped sharply to nearly zero after 1 month
from acquiring it. These three studies also suffered from a high
overall attrition rate of more than 30% and the intervention
groups lost more participants than the control groups. Another
calorie-counting app FatSecret was tested as an addition to a
weight-loss podcast made and previously proven effective by the
same study team. The results showed no difference in weight loss
between the groups.30
The Schoeppe 2016 systematic review assessed studies aimed
at improving diet, physical activity and sedentary behavior.14 It
included 20 RCTs, 3 controlled trials and 4 pre-post studies, but
only 8 RCTs were relevant to this overview. It synthesized the trials
in tabular and narrative formats, and assessed the quality of the
trials using the CONSORT checklist.31 Two of the RCTs tested so-
called 'exergame' (gamiﬁed exercise) apps called Zombies! Run,
The Walk, non-immersive app Get Running and an activity
monitoring app MOVES.32,33 Both studies had very low attrition
rates, but failed to demonstrate any signiﬁcant between group
differences in improvements in physical activity and its indicators
and predictors such as cardiorespiratory ﬁtness, enjoyment of
exercise and motivation.
One trial assessed an app aimed at increasing vegetable
consumption called Vegethon on a small sample of participants of
a 12-month weight loss program.34 People who used the app
consumed more servings of vegetable per day than the control
group at 12 weeks (adjusted mean difference 7.4, 95% CI 1.4–13.5;
p= 0.02). Another physical activity trial tested a tablet-based app
ActiveLifestyle among independently living seniors.35,36 Between-
groups comparisons revealed moderate effect for gait velocity
(Mann–Whitney U= 138.5; p= .03, effect size r= .33) and cadence
(Mann–Whitney U= 138.5, p= .03, effect size r= .34) during dual
task walking at preferred speed in favour of the tablet-based app
groups.
There were two apps that were tested in two different studies
included in both the Flores-Mateo and Schoeppe systematic
reviews. The Lose-It! app was tested for 6 months27 and for
8 weeks.37 Not only was there no difference in weight loss
between groups, in the second study the app group lost less
weight than the two control groups that used a paper diary and
the memo function of the phone. In contrast, the AccupedoPro
pedometer app demonstrated a similar amount of increase in
daily steps both in general primary care patients38 and in young
adults.39
Risk of bias in included systematic reviews
The overall results of risk of bias in the six systematic reviews
evaluated by the Cochrane risk of bias in systematic reviews
(ROBIS) tool40 is presented in Table 3. Overall, ﬁve of the reviews
had high risk of bias and one had low risk. ROBIS assessment has
three phases: the ﬁrst one (optional) assesses the relevance of
included reviews to the overall review question (not reported
here). The second phase evaluates detailed risk of bias in four
domains (Table 3). The ﬁrst domain (study eligibility criteria)
revealed that none of the systematic reviews had a published
protocol specifying their eligibility criteria and analysis methods.
However, the detailed information provided in their methods
sections regarding eligibility and analyses, combined with the rest
of the domain questions made it possible for us to evaluate the
whole domain low risk of bias for all the reviews. The main issue
with the second domain (study identiﬁcation and selection) was
limiting the literature search to only English language publica-
tions. We considered this to be a serious hurdle in retrieving as
many eligible studies as possible because many Spanish and
Portuguese speaking countries as well as many European
countries are conducting and publishing mHealth research
Table 3. Overall results of risk of bias in systematic reviews (ROBIS) assessment
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actively. The third domain (data collection and study appraisal)
had issues around lack of information about the effort to minimize
error in data collection and failure to formally assess the risk of
bias in the primary studies. In the last domain of phase 2
(synthesis and ﬁndings), the reviews received “no” on reporting of
all pre-deﬁned analysis or explaining departures due to lack of
published protocols, relating back to domain 1. Also, the risk of
bias levels in the primary studies was neither minimal nor
sufﬁciently addressed in the synthesis in all but one review.
Phase 3 assesses the overall risk of bias of the systematic review.
The main issue in this summary of risk of bias was with the ﬁrst
signalling question asking if the reviews addressed the concerns
identiﬁed in the previous four domains in their discussions. All
studies failed to recognize and address the potential sources of
risk of bias that were identiﬁed in the domains of phase 2.
DISCUSSION
Principal ﬁnding
Our overview evaluated six systematic reviews that included 23
RCTs of 22 currently available stand-alone health apps. Eleven of
the 23 trials showed a meaningful effect on health or surrogate
outcomes attributable to apps (Table 2). However, the overall
evidence of effectiveness was of very low quality,41 which hinders
the prescribability of those apps. Most of the app trials were pilot
studies, which tested the feasibility of the interventions on small
populations for short durations. Only one of the pilot trials has
progressed on to a large clinical trial.17 The most commonly trialed
apps have been designed to address conditions with the biggest
global health burden: diabetes, mental health, and obesity.
Although there is widespread acceptance of smartphones and
promise of health apps, the evidence presented here indicates few
effectiveness trials of health apps have been conducted. The risk
of bias of both the included reviews and the primary studies is
high. The reviews lacked sensitivity analyses to integrate the risk
of bias results into context. Some of the RCTs also suffered from
high attrition rates, and sometimes attrition was greater in the
intervention group than the control group21,22; thus compromis-
ing the positive results and the conclusions drawn from the
studies.
Strengths
Although we set out to do a traditional overview of systematic
reviews, it quickly became apparent that in order to ascertain the
availability of the stand-alone mHealth apps, which was crucial to
our objectives, we needed to investigate the primary trials
evaluating the apps. We have provided a window into the body
of evidence on currently available stand-alone mHealth apps with
a special focus on the 'prescribability' in general practice settings,
because this is where effective stand-alone apps can beneﬁt both
general practitioners and patients. It is also possible for other
primary care practitioners, such as diabetes nurses and phy-
siotherapists, to prescribe suitable health apps to patients.
There are a number of previous overviews of systematic reviews
in eHealth and mHealth areas that can be comparable to ours in
scope and methodology.42–46 Two of these used the Overview
Quality Assessment Questionnaire and the others used the
AMSTAR tool to assess the quality of the included systematic
reviews.47,48 We chose to use Cochrane’s newly developed ROBIS
tool, which focuses more on the risk of bias attributes and the
quality of the methods compared to AMSTAR.49 Also, we did not
restrict our search to any one language as many of the overviews
did. Overviews are often limited by the individual limitations of
the included systematic reviews, lack of risk of bias assessments,
and challenge of synthesizing the overall results, and ours is no
exception. We sought to overcome these limitations by contacting
an extensive list of primary study authors to ﬁll in the gaps left by
the systematic reviews, and by assessing the risk of bias of
included reviews vigorously. Despite these differences in metho-
dology, our ﬁndings echo the conclusions of all the overviews
regarding low quality of evidence in mHealth and eHealth areas
they investigated. However, each of these overviews covered
mixture of interventions, ranging from text messages, web tools,
phone calls to apps, making them general and broad. We aimed to
make our study more useful by exclusively focusing on a speciﬁc
type of mHealth intervention with a vision of practical application
in general practice.
Limitations
Our review was limited by the weaknesses in the systematic
reviews we identiﬁed. The systematic reviews did not thoroughly
adhere to the PRISMA statement50 by not assessing the included
studies’ risk of bias or not integrating the risk of bias results into
the overall synthesis, thus preventing the reader from recognizing
the poor quality of the included studies. The lack of understanding
of risk of bias assessment prevented the authors from addressing
this limitation in their discussions, as was evident during our ROBIS
assessment. In addition, our overview was unable to assess the
RCTs of health apps published in the past year because they are
yet to be included in any systematic reviews and we speciﬁcally
aimed to synthesize only systematic reviews. This highlights the
necessity of timely updates of high levels of evidence in this ﬁeld,
which is further discussed in the ‘Implications for research’ section.
Furthermore, information regarding app availability was often
not available in the primary studies. Thus, to compile the
information on practical issues in Table 2 and to determine the
current availability of apps, we had to contact primary study
authors and search in the app stores. This emphasizes the
importance of providing complete and transparent reporting of
app interventions,51 as is true of other interventions in health
care.52 We believe that sharing information amongst researchers
working in app development is vital to reduce research waste and
prevent re-invention of wheels.53 We also found several cases
where, despite the initial trials failing to demonstrate any positive
beneﬁt, the apps were still released (Table 2), adding to the ‘noise’
rather than the ‘signal’ in this ﬁeld, and leading to opportunity
costs. In other cases, app testing and release were terminated due
to lack of ongoing funding as the technology requires constant
updates and improvements. Thus, it is important to secure a
necessary funding source before engaging in an app development
and testing efforts.
Implications for practice
At present, anyone can create and publish health and medical
apps in the app stores without having to test them, and patients
must experiment with apps by trial and error. If GPs are to
prescribe health apps, then they must be conﬁdent that the apps
are shown to work, have fair privacy and data safety policies, and
are usable at the very least. However, both assessment of
individual apps and literature searches on app evidence are
highly time-consuming and challenging for doctors to do on their
own. Hence, we suggest that an independent and reliable source
to carry out the evaluation of apps and to provide a collection of
trustworthy mHealth apps is vital in providing doctors with
prescribable apps.
The recently re-opened NHS Apps library is a great example of
such source of apps for doctors’ use, despite the initial hurdles
with the data safety of some of their previously recommended
apps.54 They now employ a US-based app called AppScript, which
contains all the apps in the NHS App library, to make app
prescribing even easier for doctors.55 There have been numerous
efforts around the world to provide quality and efﬁcacy
assessments of mHealth apps, each devising and using their
own app evaluation framework. The challenges and the
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complexity of those efforts are well summarized by Torous et al.56
Thus, we believe initiatives like NHS App library are the safer and
more accountable way to implement digital interventions in real
practice. Like clinical guidelines, a recognized national body can
decide what framework they want to use to evaluate apps and
which apps to deem safe for use in practice in that particular
country.
Implications for research
Our overview found a number of methodological shortcomings in
evaluation of mHealth apps. Consistent sources of high risk of bias
in the primary RCTs were failure to blind participants and
personnel to the intervention, as well as poor reporting of
allocation concealment. Although blinding can be challenging in
mHealth studies, it is important because of the digital placebo
effect.57 Creating and using a basic static app or sham app for the
control groups can help account for digital placebo effect and
help establish the true efﬁcacy of the interventions. Allocation
concealment in mHealth trials can be done in the same way as in
any other RCT by employing personnel who do not have any
contact with the participants to handle the app installations;
however, hardly any RCTs tried to ensure this. Several studies also
noted that the control groups were susceptible to contamination
with apps using the same or similar interventions to the tested
app, since there are thousands of apps freely available to them
outside of the research setting.29,58 A solution to this issue would
be to increase the sample size to allow for drop-ins to the study
intervention or similar ones, and to measure the usage of the apps
to assess the contamination. Lastly, the only way to establish the
effect of an intervention is by demonstrating greater change in
one group compared to the other, rather than comparing it to the
baseline.59 Yet, many RCTs failed to report their results as
between-group differences and to adhere to the relevant
guideline.31
The value of RCTs to evaluate fast-evolving mHealth interven-
tions has been challenged due to their long duration, high cost
and rigid designs. Although multitude of modiﬁcations and
alternative methods have been suggested, widespread consensus
is yet to be reached.60–62 As our overview showed, the effect of
apps as health interventions might be marginal, and such small
beneﬁts can only be reliably detected by rigorous testing. Thus,
RCTs should remain the gold standard, but should be employed
strategically, and only used when the intervention is stable, can be
implemented with high-ﬁdelity, and has a high likelihood of
clinically meaningful beneﬁt.63
We also emphasize the value of traditional systematic and other
reviews. The role of these higher levels of evidence is not only to
assess and summarize the evidence in a ﬁeld, but also to reveal
the gaps and shortcomings in existing research, which our
overview has done. If a review ﬁnds that the base of the evidence
pyramid is shaky, that is the trials being done are not of high
quality, then we must endeavour to ﬁx it. The traditional reviews
are also incorporating new technology. The Cochrane
Collaboration’s recent advance in the area of living systematic
reviews that are 'continually updated, incorporating relevant new
evidence as it becomes available', offers signiﬁcant opportunity to
reduce the amount of time and effort it takes to update high level
evidence.64,65 This will be invaluable in digital health research and
evidence base building. As the supporting technologies of
automation and machine learning continue to improve and
become widespread, more time and human effort will be saved,
and the easier it will be to update the evidence.66
CONCLUSION
Smartphone popularity and mHealth apps provide a huge
potential to improve health outcomes for millions of patients.
However, we found only a small fraction of the available mHealth
apps had been tested and the body of evidence was of very low
quality. Our recommendations for improving the quality of
evidence, and reducing research waste and potential harm in this
nascent ﬁeld include encouraging app effectiveness testing prior
to release, designing less biased trials, and conducting better
reviews with robust risk of bias assessments. Without adequate
evidence to back it up, digital medicine and app 'prescribability'
might stall in its infancy for some time to come.
METHODS
The Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) reporting guideline and the Overview of
Reviews chapter (Chapter 22) of the Cochrane Handbook of
Systematic Reviews of Interventions Version 5.1.0 were used as
general guides to conduct this overview.50,67
Inclusion criteria
We included systematic reviews that evaluated at least one RCT of
a currently available stand-alone health app. When the systematic
review included other types of primary studies as well as RCTs, we
reported only on the results of the RCTs. Our inclusion criteria are
summarized in Table 4.
Exclusion criteria
We excluded systematic reviews if they did not include any RCTs
(i.e., included only case-control or cohort or other observational
studies), included RCTs of apps that are not stand-alone or
currently available; focused only on content evaluation of apps;
reported no measurable health outcome; or were feasibility trials
of app development; and used the following interventions: text or
voice messages; apps aimed at health professionals; appointment
and medication reminder apps; PDAs, video games, consoles, or
other devices; or only native smartphone features such as built-in
GPS and accelerometer. We also excluded study protocols and
conference abstracts, of which the full text articles were not found.
Table 4. Summary of inclusion criteria
Population Patients of all ages, gender and races, with any type of health conditions
Intervention Stand-alone smartphone or tablet apps that are readily available from leading app stores
Comparison No intervention, treatment as usual, traditional or paper-based interventions, waitlist, or another recognized treatment
Outcome Objective measurable health outcomes (e.g., reduction in HbA1c, waist circumference, BMI or weight loss), quality of life outcomes and
mood and behaviour changes reported according to relevant and validated questionnaires (e.g., Depression and Anxiety Stress Scale
(DASS)).
Study design Systematic reviews of RCTs (if the systematic reviews included other study designs, we will only report on the results of the relevant
RCTs)
Time limit Systematic reviews published from 2008 and onwards
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Search methods
Electronic database searches. We searched four electronic data-
bases for systematic reviews without language restrictions:
Medline Ovid, Cochrane Database of Systematic reviews, EMBASE,
and Web of Science from 1 January 2008 through 1 February 2017.
The cut-off date of 2008 was chosen as it coincides with the
release of smartphones capable of running third-party Apps and
when the two major App stores opened. We developed the initial
search terms for Medline Ovid, and then modiﬁed them for other
databases. Our search terms included combinations, truncations,
and synonyms of 'cell phone', 'smartphone', 'application', 'inter-
vention', 'patient', 'public', 'outcome', 'effectiveness', 'improve-
ment', 'reduction', 'review' and 'meta-analysis'. The full search
strategy for all databases is provided as Supplementary Informa-
tion 3.
Searching other resources. In addition to the search of electronic
databases, we did forward and backward citation searches of
included systematic reviews, and hand-searched the Journal of
Medical Internet Research (JMIR) from inception. We also contacted
the authors of potentially includable trials to ascertain the
availabilities and the progress of the app interventions as it was
often unclear whether the apps were released, discontinued, or
still in testing with plans for release. Additionally, we contacted
many authors of trials that used text messages, PDA apps and
web-based interventions to ﬁnd out if those interventions were
developed into smartphone apps.
Data collection and analysis
Selection of reviews. Two authors (O.B., P.G.) screened titles and
abstracts of the search results independently. We then retrieved in
full text articles and one author (O.B.) assessed them according to
the inclusion criteria outlined above with the second author (P.G.)
assessing a random sample. Where the eligibility of the studies
could not be determined due to insufﬁcient information supplied
in the abstract or absence of an abstract, the full text articles were
obtained. Any disagreements between reviewers were resolved by
discussion and consensus or by consulting with a third author (E.
B.). When more than one publication of a study was found, the
most recent and or the most complete one was used for data
analysis. Systematic reviews excluded after full text review are
provided as Supplementary Information 1 and 2 with reasons for
exclusion.
Data extraction and assessment of risk of bias. Two authors (O.B.,
S.S.) independently extracted the following data from the included
systematic reviews using a form developed by the authors for this
review: study ID (ﬁrst author’s last name and publication year),
study characteristics (population, intervention, comparator, out-
come, study design) and limitations of the review. We also
extracted data from the RCTs of currently available stand-alone
health apps. Along with general study characteristics information,
we presented information gathered via contacting the authors for
the availability of the intervention apps and other practical issues
regarding their prescribability. Two authors (O.B., S.S.) assessed the
risk of bias of the included systematic reviews according to
Cochrane’s Risk of Bias in Systematic reviews (ROBIS) tool.40 Any
disparities were resolved by consulting with a third author (E.B.).
Data availability
All data generated or analysed during this study are included in
this published article and its Supplementary Information ﬁles.
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